However, given the diversity of HuR functions in different pathological settings, future research should aim to develop drugs that can precisely regulate HuR function to both block its pro-cancer effects and maintain or enhance its anti-inflammatory potential in CRC. This evidence concerns the gene ELAVL1 and colorectal carcinoma.